Return on Sales by Net Profit: Adlai Nortye Ltd. (ANL)

adlainortye.com - graphic logo of issuer ANL

International leadership experience in developing oncology drugs has laid the foundation for Adlai Nortye Ltd. (ANL) business expansion. The net profitability trend visualizes this growth, where -124.80 reflects the latest metric value. The development of innovative buparlisib against resistant tumors enhances the company's potential, while the expansion of its center network in Asia and the US, coupled with full patient retention, ensures stability ahead of FDA approval.

Adlai Nortye (ANL) Net Return on Sales: for the period 02/21/2024 - 11/20/2026

Adlai Nortye Ltd (ANL) - metric breakdowns and financial figures

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:Adlai Nortye Ltd, ANL
Manufactured product of Adlai Nortye

Geopolitical tensions and sanctions between China and the US are hindering the global clinical trials of Adlai Nortye Ltd. (ANL). These logistical disruptions directly impact operating expenses, distorting bottom-line profits. This metric measures the share of net income in total revenue, determining the real efficiency of the business. This metric allows for an assessment of the issuer's financial stability and helps avoid overpaying for the asset. An analysis of the net profit margin trend confirms the company's ability to generate profit.

Analysis of competing companies

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)